C Sixty Inc. (CNI)
C Sixty is an early stage, highly innovative and focused nanotechnology company pioneering the development of new drugs based on the unique chemistry of water-soluble fullerenes, a recently discovered class of highly structured, small molecules. Since its organization in 1999, C Sixty has secured and developed a strong intellectual property position covering the strategic biomedical uses of fullerenes. Beginning in 2003, the Company has focused its drug discovery efforts on the unprecedented antioxidant activity of fullerenes. C Sixty believes that drugs based on fullerene antioxidant molecules may have significant impact on several unsolved diseases, including: Parkinson's Disease, Alzheimer's, Stroke, Atherosclerosis, complications from Diabetes, and protection of bone marrow cells from cancer chemotherapy and radiotherapy, each of which represent billion dollar annual market opportunities. C Sixty has secured partnerships with at least two multinational life science partners (Merck and Unilever). These partnerships currently involve evaluation of C Sixty’s drug candidates for specific target applications. C Sixty is a wholly owned subsidiary of Carbon Nanotechnologies Inc (CNI), the leading producer and innovator in the area of single-walled carbon nanotubes, and is managed as an independent operating company.
Source: C Sixty Inc.